<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321890</url>
  </required_header>
  <id_info>
    <org_study_id>2016-FXY-079-内科</org_study_id>
    <nct_id>NCT03321890</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)</brief_title>
  <official_title>A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide,
      etoposide and methotrexate in relapsed or refractory PTCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prednisone, cyclophosphamide, etoposide, and methotrexate regimens are derived from a
      &quot;metronidazole, etoposide, procarbazine and cyclophosphamide (PEPC) regimen&quot; regimen that
      differs from the traditional &quot;maximal Tolerance &quot;chemotherapy, and the use of low-dose
      chemotherapy, frequent drug therapy, the purpose is to anti-angiogenesis and reduce drug
      resistance. At present, the program in our treatment of relapsed or refractory PTCL patients
      effective, safe and controllable, but also look forward to other joint treatment, so as to
      achieve better curative effect. To provide new treatment options for such patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>every 8 weeks until 2 years after last patient's enrollment</time_frame>
    <description>the total proportion of patients with complete response（CR or CRu）and partial response（PR）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>every 8 weeks until 2 years after last patient's enrollment</time_frame>
    <description>Duration of complete response（CR or CRu）and partial response（PR）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival(PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Time from treatment until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from treatment until death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Combination therapy regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast</description>
    <arm_group_label>Combination therapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>oral, 20mg / day,after breakfast</description>
    <arm_group_label>Combination therapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>oral, 50mg / day,after lunch</description>
    <arm_group_label>Combination therapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>oral, 50mg / day,after dinner</description>
    <arm_group_label>Combination therapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>oral, 10mg / times, once a week,after breakfast</description>
    <arm_group_label>Combination therapy regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically confirmed peripheral T-cell lymphoma (PTCL) patients;

          2. Patients who have had at least one systemic treatment (including chemotherapy,
             hematopoietic stem cell transplantation, etc.) who have not remission or relapsed
             after remission;

          3. For various reasons can not be hematopoietic stem cell transplantation in patients;

          4. The age of 18-75 years old, male, female open;

          5. ECOG (Eastern Cooperative Oncology Group) physical scoring 0-1 points;

          6. Absolute value of neutrophil≥1.5 × 109 / L, platelet≥90 × 109 / L, hemoglobin≥90g / L;

          7. The expected survival time ≥ 3 months;

          8. No radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell
             transplantation were performed within 4 weeks prior to enrollment.

          9. Voluntary signature of written informed consent.

        Exclusion Criteria:

          1. Pregnancy, breastfeeding women and unwilling to take contraceptive measures of
             reproductive age patients;

          2. B-mode ultrasonography showed that the width of end-diastolic pericardial dark area
             was ≥10mm;

          3. Patients receiving organ transplants;

          4. Patients receiving symptomatic treatment of pre-bone marrow toxicity within 7 days
             prior to enrollment;

          5. Patients with active bleeding;

          6. Liver function abnormalities (total bilirubin&gt; 1.5 times the upper limit of normal,
             ALT( alanine aminotransferase) / AST (Aspartate aminotransferase)&gt; 2.5 times the upper
             limit of normal or hepatic involvement of ALT / AST&gt; 5 times the upper limit of
             normal), renal dysfunction Creatinine&gt; 1.5 times the upper limit of normal),
             electrolyte abnormalities;

          7. Persons with mental disabilities / those who can not obtain informed consent;

          8. Patients with drug abuse and long-term alcohol abuse that may affect the evaluation of
             test results;

          9. The investigators determined that they were not fit to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenqi Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical Oncology,Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiming Li, MD</last_name>
    <phone>86-20-87343765</phone>
    <email>lizhm@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Wang, MD</last_name>
    <phone>86-20-87343349</phone>
    <email>wangyu@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medical Oncology,Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiming Li, DM</last_name>
      <phone>+86-13719189172</phone>
      <email>Lizhm@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yu Wang, DM</last_name>
      <phone>86-20-87343765</phone>
      <email>Wangyu@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhiming</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>relapsed or refractory</keyword>
  <keyword>peripheral T-cell lymphoma</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

